By successfully encapsulating a vaccine into a spider silk microparticle, Swiss and German researchers have discovered a novel technique that will help fight cancer and certain infectious diseases.
To fight cancer, researchers increasingly use vaccines that stimulate the immune system to identify and destroy tumour cells. However, the desired immune response is is not always guaranteed. In order to strengthen the efficacy of vaccines on the immune system – and in particular on T lymphocytes, specialized in the detection of cancer cells – researchers from the universities of Geneva (UNIGE), Freiburg (UNIFR), Munich, and Bayreuth, in collaboration with the German company AMSilk, have developed spider silk microcapsules capable of delivering the vaccine directly to the heart of immune cells. This process, published in the journal Biomaterials, could also be applied to preventive vaccines to protect against infectious diseases, and constitutes an important step towards vaccines that are stable, easy to use, and resistant to the most extreme storage conditions.
Our immune system is largely based on two types of cells: B lymphocytes, which produce the antibodies needed to defend against various infections, and T lymphocytes. In the case of cancer and certain infectious diseases such as tuberculosis, T lymphocytes need to be stimulated. However, their activation mechanism is more complex than that of B lymphocytes: to trigger a response, it is necessary to use a peptide, a small piece of protein which, if injected alone, is rapidly degraded by the body even before reaching its target.
“To develop immunotherapeutic drugs effective against cancer, it is essential to generate a significant response of T lymphocytes,» says Professor Carole Bourquin, a specialist in antitumor immunotherapies at the faculties of medicine and science of the UNIGE, who directed this work. “As the current vaccines have only limited action on T-cells, it is crucial to develop other vaccination procedures to overcome this issue.”
A virtually indestructible capsule
Scientists used synthetic spider silk biopolymers—a lightweight, biocompatible, non-toxic material that is highly resistant to degradation from light and heat. “We recreated this special silk in the lab to insert a peptide with vaccine properties,» explains Thomas Scheibel, a world specialist of spider silk from the University of Bayreuth who participated in the study. “The resulting protein chains are then salted out to form injectable microparticles.”
Silk microparticles form a transport capsule that protects the vaccine peptide from rapid degradation in the body, and delivers the peptide to the center of the lymph node cells, thereby considerably increasing T lymphocyte immune responses. “Our study has proved the validity of our technique”, reveals Carole Bourquin. “We have demonstrated the effectiveness of a new vaccination strategy that is extremely stable, easy to manufacture and easily customizable.”
Towards a new vaccine model
The synthetic silk biopolymer particles demonstrate a high resistance to heat, withstanding over 100°C for several hours without damage. In theory, this process would make it possible to develop vaccines that do not require adjuvants and cold chains. An undeniable advantage, especially in developing countries where one of the great difficulties is the preservation of vaccines. One of the limitations of this process, however, is the size of the microparticles: while the concept is in principle applicable to any peptide, which are all small enough to be incorporated into silk proteins, further research is needed to see if it is also possible to incorporate the larger antigens used in standard vaccines, especially against viral diseases.
When science imitates nature
“More and more, scientists are trying to imitate nature in what it does best”, adds Scheibel. “This approach even has a name: bioinspiration, which is exactly what we have done here.” The properties of spider silk make it a particularly interesting product: biocompatible, solid, thin, biodegradable, resistant to extreme conditions and even antibacterial, one can imagine multiple applications, including wound dressings or sutures.
Learn more: A new kind of vaccine based on spider silk
The Latest on: Vaccine delivery
[google_news title=”” keyword=”vaccine delivery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Vaccine delivery
- DRC is seeing its worst mpox outbreak — but has no vaccines or treatments yet. Why?on April 26, 2024 at 5:07 pm
With nearly 5,000 cases reported so far this year — and concerns about a new strain — the Democratic Republic of Congo is considering the declaration of a public health emergency.
- Breakthrough Vaccine Shows High Protection Against Drug-Resistant Superbug in Miceon April 26, 2024 at 4:03 pm
Scientists have developed a vaccine against a notorious drug-resistant superbug, targeting molecules on its surface that are also found on other bacteria and fungi. Although only tested in mice, the ...
- Acuitas, CureVac settle lawsuit over COVID-19 vaccine patent rightson April 25, 2024 at 2:27 pm
Biotech company Acuitas Therapeutics and Germany-based CureVac have settled Acuitas' lawsuit demanding credit for inventions related to COVID-19 vaccines, according to a filing on Thursday in Virginia ...
- A Vaccine to Fight Antibiotic Resistanceon April 25, 2024 at 2:25 pm
MSU, Harvard Medical School team up to expand vaccine science’s role in the fight against MRSA and other infections ...
- Vaccine breakthrough means no more chasing strainson April 25, 2024 at 11:10 am
Scientists at UC Riverside have devised a vaccine that targets a part of the viral genome that is common to all strains of a given virus.
- Vaccines Protect Moms And Babies From Maternal And Neonatal Tetanus In Malion April 25, 2024 at 7:31 am
Mali successfully eliminated MNT with support from UNICEF and partners. One mother shares how she became a vaccine advocate after losing her newborn to tetanus.
- Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earningson April 25, 2024 at 6:47 am
Vaccine sales increased by 5.6% to 1.2 billion euros ... No Beyfortus sales are expected in Q2 2024 due to the early delivery in Q1 and the specific seasonality. Read Next: Amgen/AstraZeneca’s Asthma ...
- Vaccines are a glimmer of hope against malaria, but the battle has only just begunon April 25, 2024 at 6:10 am
By the time you reach the end of this article, three children will have died from malaria – a disease that casts a dark shadow over nearly half of the world’s population, claiming victims ...
- Researchers develop vaccine to fight antibiotic resistanceon April 24, 2024 at 11:37 pm
Driven by the overuse of antimicrobials, pathogens are quickly building up resistances to once-successful treatments. It’s estimated that antimicrobial-resistant infections killed more than 1 million ...
via Bing News